<DOC>
	<DOCNO>NCT01663961</DOCNO>
	<brief_summary>A study evaluate interaction healthy subject heart drug Digoxin YM178 , latter take continuous basis , order establish risk patient may take combination drug .</brief_summary>
	<brief_title>A Study Evaluate Effect Single Dose Digoxin Actions Bodies Healthy Subjects After Having Taken Several Doses YM178</brief_title>
	<detailed_description>Subjects receive single oral dose digoxin Day 1 . A full pharmacokinetic profile digoxin obtain 144 hour post-dose . On morning Day 7 , schedule assessment do , subject leave clinic return Day 9 . From Day 10 include Day 23 , subject receive daily oral dos YM178 q.d . A single dose digoxin give combination YM178 Day 18 ( 8 day first dose YM178 ) . On day , complete pharmacokinetic profile digoxin obtain 144 hour post-dose . From Day 16 include Day 19 , blood sample bioanalysis YM178 take regularly . In addition , vital sign , safety ECG ( Electrocardiogram ) measurement , safety laboratory assessment , adverse event concomitant medication monitor throughout investigational period . Subjects return Post Study Visit 7-14 day last dosing occasion .</detailed_description>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Female subject must nonchild bear potential , i.e . post menopausal , surgically sterilize ( e.g . tubal ligation ) , hysterectomy medical history , must practice adequate ( double barrier ) nonhormonal contraceptive method prevent pregnancy Body Mass Index â‰¥ 18.5 &lt; 30 kg/m2 History presence cardiac disease , include arrhythmia ( include 1st 2nd degree atrioventricular heart block ) History hypokalemia , hypercalcemia hypomagnesemia Any liver function test ( i.e . ALT , AST Alkaline phosphatase ) upper limit normal repeated measure Any clinically significant history asthma , eczema , clinically significant allergic condition previous severe hypersensitivity drug ( exclude nonactive hay fever ) Any clinically significant history gastrointestinal symptom 4 week prior admission clinical unit A marked baseline prolongation QT/QTc interval repeat measurement &gt; 450 m , history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsades de pointes , structural heart disease , family history Long QT Syndrome ( LQTS ) Regular use inducer liver metabolism ( e.g . barbiturate , rifampin ) 3 month prior admission clinical unit Positive serology test HBsAg , anti HAV ( IgM ) , antiHCV antiHIV 1+2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>YM178 Oral Controlled Absorption System ( OCAS )</keyword>
	<keyword>Digoxin ( Lanoxin )</keyword>
	<keyword>DDI ( Drug-drug interaction )</keyword>
	<keyword>Open-label</keyword>
	<keyword>Steady-state</keyword>
	<keyword>subject</keyword>
</DOC>